Publications
Featured Publications
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)
Journal for ImmunoTherapy in Cancer (JITC)
November 2023
Preclinical efficacy and immune activity of half-life extended IL-18 fusion proteins resistant to IL-18BP suppression
Society for Immunotherapy of Cancer (SITC)
November 2024
Tumor microenvironment pharmacodynamic effect of nemvaleukin less frequent intravenous dosing in multiple solid tumors: results from the phase 1/2 ARTISTRY-3 study
Society for Immunotherapy of Cancer (SITC)
November 2024
All Publications
ARTISTRY-7: Phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer
Future Oncology
June 2023
ARTISTRY-7: Phase 3, Multicenter Study of Nemvaleukin Alfa Plus Pembrolizumab Versus Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
American Society of Clinical Oncology (ASCO) Annual Meeting
June 2023
ARTISTRY-6: Nemvaleukin Alfa Monotherapy in Patients With Advanced Mucosal and Cutaneous Melanoma
American Society of Clinical Oncology (ASCO) Annual Meeting
June 2023
A Novel Murine Tumor Model for Assessing the Efficacy of Neoadjuvant Dosing Regimens for Immunotherapies
American Association for Cancer Research (AACR) Annual Meeting
April 2023
A Novel Murine Tumor Model for Assessing the Efficacy of Neoadjuvant Dosing Regimens for Immunotherapies
American Association for Cancer Research (AACR) Annual Meeting
April 2023
Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors: ARTISTRY-1
European Congress on Gynaecological Oncology (ESGO) Congress
October 2022
Using Low Dose and Intermediate-affinity IL-2 receptor agonist (Nemvaleukin alfa) with XRT to address PD1 Resistance
American Society for Therapeutic Radiology and Oncology ( ASTRO) Annual Meeting
October 2022
ARTISTRY-7: Phase 3, Multicenter Study of Nemvaleukin Alfa Plus Pembrolizumab Versus Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
American Society of Clinical Oncology (ASCO) Annual Meeting
June 2022
Use of Quantitative System Pharmacology (QSP) Modeling to Optimize Dosing Frequency and Interval for Nemvaleukin Alfa, an Investigational Cancer Immunotherapy
Population Approach Group Europe (PAGE) Meeting
June 2022
Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors: ARTISTRY-1
American Society of Clinical Oncology (ASCO) Annual Meeting
June 2022
ARTISTRY-3: Effect of Nemvaleukin Alfa With a Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on the Tumor Microenvironment in Patients With Advanced Solid Tumors
American Society of Clinical Oncology (ASCO) Annual Meeting
June 2022
ARTISTRY-6: Nemvaleukin Alfa Monotherapy in Patients With Advanced Mucosal and Cutaneous Melanoma
American Society of Clinical Oncology (ASCO) Annual Meeting
June 2022